{"cdcTestId":"2022-0021","testcaseName":"3rd dose of Covid-19 Vaccine different product (Pfizer ) than second dose (Moderna)","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-09-05T00:00:00","patient":{"dob":"1965-08-13T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2021-06-16T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-05-21T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-06-18T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"4","earliestDate":"2022-08-13T00:00:00","recommendedDate":"2022-08-13T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2021-06-16T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-05-21T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-06-18T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T11:11:37.351","generalDescription":"This test case describes when a patient is administered a Pfizer Covid-19 vaccine (third dose) 28 days after a second dose Moderna vaccine, that the dose is valid.  A booster dose (preferably a bivalent mRNA) should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated test case Assessment Date to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group."}